Travere Therapeutics (TVTX) Stock: Why It's Up Today
Updated Oct 19, 2026, 12:05 PM ET · intraday price
- Trading at $50.82 as of 12:05 PM ET, +2.46% vs the prior close of $49.60.
- Volume 429.00K shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
TVTX rises 2.5% to $50.82. Trading at $50.82 (intraday, 12:05 PM ET), +2.46% vs the prior close of $49.60. Day range $49.74–$51.28, opened at $50.17.
TVTX daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — TVTX rises 2.5% to $50.82
- Trading at $50.82 (intraday, 12:05 PM ET), +2.46% vs the prior close of $49.60. Day range $49.74–$51.28, opened at $50.17.
- Volume was 429.00K shares, 0.3x its 50-day average of 1.58M — lighter than usual.
- Price is -16.9% vs its 50-day average ($61.16) and +10.8% vs its 200-day average ($45.88).
- 52-week range $22.59–$68.73; the current price sits at 61% of that range, 26.1% below the 52-week high.
Oct 16, 2026 — TVTX slides 6.0% to $49.60, a 3-month low
- Closed at $49.60, -6.04% vs the prior close of $52.79. Day range $49.46–$52.56, opened at $52.56.
- Volume was 1.83M shares, 1.1x its 50-day average of 1.60M.
- Price is -19.2% vs its 50-day average ($61.37) and +8.3% vs its 200-day average ($45.82).
- 52-week range $22.59–$68.73; today's close sits at 59% of that range, 27.8% below the 52-week high.
Oct 15, 2026 — TVTX dips 0.9% to $52.79
- Closed at $52.79, -0.90% vs the prior close of $53.27. Day range $52.63–$55.57, opened at $53.94.
- Volume was 1.98M shares, 1.2x its 50-day average of 1.69M.
- Price is -14.3% vs its 50-day average ($61.63) and +15.4% vs its 200-day average ($45.76).
- 52-week range $22.59–$68.73; today's close sits at 65% of that range, 23.2% below the 52-week high.
Oct 14, 2026 — TVTX rises 2.8% to $53.27
- Closed at $53.27, +2.84% vs the prior close of $51.80. Day range $51.53–$53.94, opened at $51.61.
- Volume was 2.06M shares, 1.2x its 50-day average of 1.70M.
- Price is -13.8% vs its 50-day average ($61.83) and +16.6% vs its 200-day average ($45.69).
- 52-week range $22.59–$68.73; today's close sits at 66% of that range, 22.5% below the 52-week high.
Oct 13, 2026 — TVTX dips 0.4% to $51.80, a 3-month low
- Closed at $51.80, -0.42% vs the prior close of $52.02. Day range $51.38–$52.81, opened at $51.57.
- Volume was 1.67M shares, 1.0x its 50-day average of 1.70M.
- Price is -16.3% vs its 50-day average ($61.88) and +13.6% vs its 200-day average ($45.62).
- 52-week range $22.59–$68.73; today's close sits at 63% of that range, 24.6% below the 52-week high.
Oct 12, 2026 — TVTX ends flat (-0.2%) to $52.02, a 3-month low
- Closed at $52.02, -0.20% vs the prior close of $52.12. Day range $51.74–$53.35, opened at $51.74.
- Volume was 1.42M shares, 0.8x its 50-day average of 1.71M.
- Price is -16.0% vs its 50-day average ($61.95) and +14.2% vs its 200-day average ($45.56).
- 52-week range $22.59–$68.73; today's close sits at 64% of that range, 24.3% below the 52-week high.
Oct 9, 2026 — TVTX ends flat (+0.2%) to $52.12
- Closed at $52.12, +0.16% vs the prior close of $52.04. Day range $51.63–$52.71, opened at $52.04.
- Volume was 1.17M shares, 0.7x its 50-day average of 1.71M.
- Price is -16.0% vs its 50-day average ($62.02) and +14.6% vs its 200-day average ($45.48).
- 52-week range $22.59–$68.73; today's close sits at 64% of that range, 24.2% below the 52-week high.
Oct 8, 2026 — TVTX dips 2.6% to $52.04, a 3-month low, 3 down days in a row
- Closed at $52.04, -2.62% vs the prior close of $53.44. Day range $51.45–$53.44, opened at $53.44.
- Volume was 1.65M shares, 1.0x its 50-day average of 1.70M.
- Price is -16.2% vs its 50-day average ($62.13) and +14.6% vs its 200-day average ($45.40).
- 52-week range $22.59–$68.73; today's close sits at 64% of that range, 24.3% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — TVTX slides 4.5% to $53.44, a 3-month low on 2.1x normal volume
- Closed at $53.44, -4.54% vs the prior close of $55.98. Day range $53.28–$56.61, opened at $55.41.
- Volume was 3.42M shares, 2.1x its 50-day average of 1.65M — unusually heavy trading.
- Price is -14.1% vs its 50-day average ($62.20) and +17.9% vs its 200-day average ($45.31).
- 52-week range $22.59–$68.73; today's close sits at 67% of that range, 22.2% below the 52-week high.
Oct 6, 2026 — TVTX dips 2.9% to $55.98, a 1-month low on 1.9x normal volume
- Closed at $55.98, -2.93% vs the prior close of $57.67. Day range $55.16–$58.77, opened at $57.86.
- Volume was 3.11M shares, 1.9x its 50-day average of 1.62M — unusually heavy trading.
- Price is -10.1% vs its 50-day average ($62.25) and +23.8% vs its 200-day average ($45.22).
- 52-week range $22.59–$68.73; today's close sits at 72% of that range, 18.6% below the 52-week high.
Oct 5, 2026 — TVTX rises 1.3% to $57.67
- Closed at $57.67, +1.30% vs the prior close of $56.93. Day range $55.86–$58.60, opened at $57.31.
- Volume was 2.64M shares, 1.7x its 50-day average of 1.59M.
- Price is -7.4% vs its 50-day average ($62.26) and +27.9% vs its 200-day average ($45.11).
- 52-week range $22.59–$68.73; today's close sits at 76% of that range, 16.1% below the 52-week high.
Oct 2, 2026 — TVTX ends flat (+0.1%) to $56.93
- Closed at $56.93, +0.14% vs the prior close of $56.85. Day range $56.34–$57.53, opened at $57.21.
- Volume was 1.72M shares, 1.1x its 50-day average of 1.59M.
- Price is -8.6% vs its 50-day average ($62.25) and +26.5% vs its 200-day average ($45.00).
- 52-week range $22.59–$68.73; today's close sits at 74% of that range, 17.2% below the 52-week high.
TVTX bull case vs bear case (from the data)
- Price is +10.8% vs its 200-day average — above the long-term trend line.
- Annual revenue grew 110.5% in the latest fiscal year (SEC XBRL).
- Price is -16.9% vs its 50-day average — short-term trend is down.
- Latest fiscal-year net income: loss of $25.55M.
- Insider selling outweighs buying: 25 sales vs 0 open-market buys among the 25 most recent reported insider trades (Form 4, last 12 months).
- Share count up 5.7% in a year (dilution).
TVTX latest news & SEC filings
Every SEC filing by or about TVTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Rote William E. converted options/RSUs into 39,000 shares at $25.25 (≈$984.75K) on Sep 15, 2026; now holds 154,745
- Rote William E. converted options/RSUs into 39,650 shares at $17.96 (≈$712.11K) on Sep 15, 2026; now holds 194,395
- Rote William E. sold 63,907 shares at $61.99 (≈$3.96M) on Sep 15, 2026; now holds 130,488
- Rote William E. sold 29,021 shares at $62.66 (≈$1.82M) on Sep 15, 2026; now holds 101,467
- Rote William E. sold 3,000 shares at $63.65 (≈$190.95K) on Sep 15, 2026; now holds 98,467
- Rote William E. sold 270 shares at $65.31 (≈$17.63K) on Sep 15, 2026; now holds 98,197
- …plus 5 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Heerma Peter converted options/RSUs into 39,283 shares at $26.88 (≈$1.06M) on Sep 15, 2026; now holds 181,349
- Heerma Peter converted options/RSUs into 1,381 shares at $22.40 (≈$30.93K) on Sep 15, 2026; now holds 182,730
- Heerma Peter converted options/RSUs into 36,526 shares at $8.93 (≈$326.18K) on Sep 15, 2026; now holds 219,256
- Heerma Peter sold 71,938 shares at $62.05 (≈$4.46M) on Sep 15, 2026; now holds 147,318
- Heerma Peter sold 27,421 shares at $62.59 (≈$1.72M) on Sep 15, 2026; now holds 119,897
- Heerma Peter sold 1,400 shares at $63.65 (≈$89.11K) on Sep 15, 2026; now holds 118,497
- …plus 8 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Inrig Jula converted options/RSUs into 32,395 shares at $8.93 (≈$289.29K) on Sep 15, 2026; now holds 145,165
- Inrig Jula sold 25,390 shares at $62.02 (≈$1.57M) on Sep 15, 2026; now holds 119,775
- Inrig Jula sold 17,284 shares at $62.62 (≈$1.08M) on Sep 15, 2026; now holds 102,491
- Inrig Jula sold 1,600 shares at $63.69 (≈$101.90K) on Sep 15, 2026; now holds 100,891
- Inrig Jula sold 400 shares at $65.31 (≈$26.12K) on Sep 15, 2026; now holds 100,491
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Reed Elizabeth E converted options/RSUs into 37,500 shares at $15.46 (≈$579.75K) on Sep 15, 2026; now holds 142,889
- Reed Elizabeth E sold 21,926 shares at $62.03 (≈$1.36M) on Sep 15, 2026; now holds 120,963
- Reed Elizabeth E sold 13,874 shares at $62.63 (≈$868.96K) on Sep 15, 2026; now holds 107,089
- Reed Elizabeth E sold 1,400 shares at $63.69 (≈$89.17K) on Sep 15, 2026; now holds 105,689
- Reed Elizabeth E sold 300 shares at $65.31 (≈$19.59K) on Sep 15, 2026; now holds 105,389
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dube Eric M converted options/RSUs into 95,666 shares at $23.34 (≈$2.23M) on Sep 15, 2026; now holds 528,552
- Dube Eric M sold 63,498 shares at $61.99 (≈$3.94M) on Sep 15, 2026; now holds 465,054
- Dube Eric M sold 28,796 shares at $62.66 (≈$1.80M) on Sep 15, 2026; now holds 436,258
- Dube Eric M sold 3,102 shares at $63.64 (≈$197.42K) on Sep 15, 2026; now holds 433,156
- Dube Eric M sold 270 shares at $65.31 (≈$17.63K) on Sep 15, 2026; now holds 432,886
- Dube Eric M converted options/RSUs into 195,841 shares at $23.34 (≈$4.57M) on Sep 16, 2026; now holds 628,727
- …plus 5 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $169.58M (prior year $114.45M) (+48.2% vs Jun 30, 2025)
- Net income: -$34.80M (prior year -$12.76M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.37 (prior year -$0.14) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade TVTX
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 4, 2026, Feb 19, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.21% (largest 6.0%).
- Liquidity: about 1.88M shares (≈$95.69M) trade per day on average.
- 52-week position: $50.82 vs a range of $22.59–$68.73 (61% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Peter Heerma sold 8,282 shares on Sep 17, 2026.
- Latest filings: 8-K Sep 21, 2026; 10-Q Aug 4, 2026; 8-K Aug 4, 2026.
- Share count: 94.26M shares outstanding (Jul 30, 2026), +5.7% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
TVTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 50.17 | 51.28 | 49.74 | 50.82 | 429.00K |
| Oct 16, 2026 | 52.56 | 52.56 | 49.46 | 49.60 | 1.83M |
| Oct 15, 2026 | 53.94 | 55.57 | 52.63 | 52.79 | 1.98M |
| Oct 14, 2026 | 51.61 | 53.94 | 51.53 | 53.27 | 2.06M |
| Oct 13, 2026 | 51.57 | 52.81 | 51.38 | 51.80 | 1.67M |
| Oct 12, 2026 | 51.74 | 53.35 | 51.74 | 52.02 | 1.42M |
| Oct 9, 2026 | 52.04 | 52.71 | 51.63 | 52.12 | 1.17M |
| Oct 8, 2026 | 53.44 | 53.44 | 51.45 | 52.04 | 1.65M |
| Oct 7, 2026 | 55.41 | 56.61 | 53.28 | 53.44 | 3.42M |
| Oct 6, 2026 | 57.86 | 58.77 | 55.16 | 55.98 | 3.11M |
| Oct 5, 2026 | 57.31 | 58.60 | 55.86 | 57.67 | 2.64M |
| Oct 2, 2026 | 57.21 | 57.53 | 56.34 | 56.93 | 1.72M |
| Oct 1, 2026 | 58.64 | 59.58 | 56.23 | 56.85 | 2.39M |
| Sep 30, 2026 | 60.35 | 60.47 | 58.83 | 58.88 | 1.56M |
| Sep 29, 2026 | 61.04 | 61.87 | 59.33 | 59.99 | 1.57M |
| Sep 28, 2026 | 59.05 | 61.75 | 58.71 | 61.57 | 1.23M |
| Sep 25, 2026 | 60.89 | 60.89 | 59.05 | 59.44 | 1.21M |
| Sep 24, 2026 | 60.00 | 60.79 | 59.22 | 60.62 | 1.76M |
| Sep 23, 2026 | 60.39 | 60.89 | 58.32 | 59.83 | 1.71M |
| Sep 22, 2026 | 60.37 | 62.45 | 59.30 | 60.28 | 3.12M |
About Travere Therapeutics
Travere Therapeutics (TVTX) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: CA. Fiscal year ends December 31. SEC CIK 1438533.
TVTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Roy D. Baynes | Director | Jun 16, 2026 |
| Suzanne Louise Bruhn | Director | May 21, 2026 |
| Timothy Coughlin | Director | Jun 16, 2026 |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sep 17, 2026 |
| Gary A Lyons | Director | Aug 19, 2026 |
| Jeffrey A Meckler | Director | Sep 11, 2026 |
| John A Orwin | Director | May 21, 2026 |
| Sandra Poole | Director | May 21, 2026 |
| Ron Squarer | Director | May 21, 2026 |
| Brinkley Ruth Williams | Director | May 21, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | Sep 17, 2026 |
| Christopher R. Cline | CHIEF FINANCIAL OFFICER | Sep 17, 2026 |
| Eric M Dube | CHIEF EXECUTIVE OFFICER | Sep 17, 2026 |
| Peter Heerma | EVP, CHIEF COMMERCIAL OFFICER | Sep 17, 2026 |
| Jula Inrig | EVP, Head of R&D & CMO | Sep 17, 2026 |
| Elizabeth E Reed | Chief Legal Officer and GC | Sep 17, 2026 |
| William E. Rote | Chief Research Officer | Sep 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Peter Heerma | Sale | 8,282 | $65.07 |
| Sep 17, 2026 | Peter Heerma | Sale | 8,282 | $65.07 |
| Sep 17, 2026 | Peter Heerma | Sale | 8,282 | $65.07 |
| Sep 17, 2026 | Peter Heerma | Sale | 8,282 | $65.07 |
| Sep 17, 2026 | Eric M Dube | Sale | 6,802 | $64.95 |
| Sep 17, 2026 | Eric M Dube | Sale | 101,691 | $64.59 |
| Sep 17, 2026 | Eric M Dube | Sale | 6,802 | $64.95 |
| Sep 17, 2026 | Eric M Dube | Sale | 101,691 | $64.59 |
| Sep 17, 2026 | Eric M Dube | Sale | 6,802 | $64.95 |
| Sep 17, 2026 | Eric M Dube | Sale | 101,691 | $64.59 |
| Sep 17, 2026 | Eric M Dube | Sale | 6,802 | $64.95 |
| Sep 17, 2026 | Eric M Dube | Sale | 101,691 | $64.59 |
| Sep 16, 2026 | Peter Heerma | Sale | 93,604 | $63.25 |
| Sep 16, 2026 | Peter Heerma | Sale | 79,113 | $63.65 |
| Sep 16, 2026 | Peter Heerma | Sale | 93,604 | $63.25 |
TVTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $490.73M | $-25.55M | -0.29 | $37.78M |
| Dec 31, 2024 | $233.18M | $-321.55M | -4.08 | $-237.47M |
| Dec 31, 2023 | $145.24M | $-111.40M | -1.50 | $-280.02M |
| Dec 31, 2022 | $109.46M | $-278.48M | -4.37 | $-186.29M |
| Dec 31, 2021 | $131.84M | $-180.09M | -3.01 | $-14.79M |
Latest balance sheet: total assets $799.36M, total liabilities $774.84M, cash $117.73M (as of Jun 30, 2026).
TVTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $56.02 |
| May 4, 2026 | 8-K Item 2.02 (results) | $44.91 |
| Feb 19, 2026 | 8-K Item 2.02 (results) | $29.30 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $34.10 |
| Oct 30, 2025 | 8-K Item 2.02 (results) | $29.65 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $17.24 |
| Feb 20, 2025 | 8-K Item 2.02 (results) | $23.58 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $18.59 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $17.50 |
| Aug 1, 2024 | 8-K Item 2.02 (results) | — |
| May 6, 2024 | 8-K Item 2.02 (results) | — |
| Feb 15, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on TVTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 19, 2026, 12:05 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.